Search hospitals > Washington > Seattle

University of Washington

Claim this profile
Seattle, Washington 98195
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for HIV Infection
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
1050 reported clinical trials
170 medical researchers
Photo of University of Washington in SeattlePhoto of University of Washington in SeattlePhoto of University of Washington in Seattle

Summary

University of Washington is a medical facility located in Seattle, Washington. This center is recognized for care of Breast Cancer, Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Lung Cancer and other specialties. University of Washington is involved with conducting 1,050 clinical trials across 1,734 conditions. There are 170 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Michael J Wagner, MD, Christine Chung, MD, and Petter Bjornstad, MD.

Area of expertise

1Breast Cancer
Global Leader
University of Washington has run 83 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III
2Cancer
Global Leader
University of Washington has run 81 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at University of Washington

Prostate Cancer
Breast Cancer
Breast cancer
Multiple Myeloma
Lung Cancer
Stroke
Follicular Lymphoma
Brain Tumor
Esophageal Carcinoma
Asthma
Image of trial facility.

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

PF-06821497 + Enzalutamide

for Prostate Cancer

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Washington?
Where is University of Washington located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Washington accept?
What awards or recognition has University of Washington received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security